{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008293","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.039771+00:00","generated_at":"2026-06-18T00:35:37.040638+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Iterum Therapeutics reports 2022 net loss $44.4M; cash $60.8M funds to mid-2024","bullets":["Cash, cash equivalents and short-term investments $60.8M; expected to fund operations until mid-2024.","Net loss Q4 2022 $5.1M, full year $44.4M; non-GAAP net loss $6.4M and $22.9M respectively.","REASSURE trial enrollment ongoing, expected completion H1 2024; interim analysis at 50% enrollment H2 2023.","Two new US patents issued for oral sulopenem (composition and method of use), expiring no earlier than 2039.","Shareholder class action lawsuit dismissed with prejudice on January 25, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008293","json":"https://secwatch.observer/filing/0000950170-23-008293.json","markdown":"https://secwatch.observer/filing/0000950170-23-008293.md","text":"https://secwatch.observer/filing/0000950170-23-008293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023008293/0000950170-23-008293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023008293/itrm-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:35:37.040638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8b592e351269ff61fe2455895ad3ae9f5e11c1d","claim":"Iterum Therapeutics plc reported fourth quarter and year ended December 31, 2022 results: net income Net loss for the fourth quarter and full year 2022 was $5.1 million and $44.4 million, respectively, compared to a net l.","evidence_excerpt":"Iterum Therapeutics plc issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023008293/0000950170-23-008293-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the fourth quarter and full year 2022 was $5.1 million and $44.4 million, respectively, compared to a net l"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}